NANOSPHERE/TAKARO BIO FORM DEVELOP/DISTRIBUTE ALLIANCE.Nanosphere, Inc., Northbrook, Ill., a privately held nanotechnology-based life sciences company, has signed a letter of intent to form a development and distribution alliance with Takara Bio Inc., one of Japan's leading biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. . In the alliance, Takara will have exclusive distribution rights for certain Nanosphere products in Asia and non-exclusive rights in European countries. The alliance also includes the development of highly sensitive, selective and portable detection systems that combine Nanosphere's proprietary nanoparticle DNA probe DNA probe An agent that binds directly to a predefined sequence of nucleic acids. Mentioned in: Legionnaires' Disease DNA probe, n See deoxyribonucleic acid probes. technology with Takara's proprietary ICAN ICAN International Cesarean Awareness Network Inc ICAN Integrated Composite Application Network (SeeBeyond) ICAN Institute of Chartered Accountants of Nigeria ICAN Idaho Community Action Network (TM) isothermal i·so·ther·mal adj. Of, relating to, or indicating equal or constant temperatures. isothermal, isothermic having the same temperature. gene amplification Gene amplification The process by which a cell specifically increases the copy number of a particular gene to a greater extent than it increases the copy number of genes composing the remainder of the genome (all the genes which make up the genetic machinery technology. Takara also will be making an equity investment in Nanosphere. "Nanosphere is very pleased to be working with Takara, an established leader in biotechnology product development and distribution. This alliance provides Nanosphere with a premier distribution partner in Asia and access to robust ICAN technology that will enable rapid market introduction of a powerful research system in the Asian marketplace," said Bill Athenson, Nanosphere's vice president of Business Development. Nanosphere's technology utilizes state-of-the-art bio-diagnostic nanoparticle probes and proprietary bio-molecular detection systems to provide rapid and effective processes for nucleic acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. and protein identification. As published in the February 22, 2002 issue of "Science," the technology has 1,000 times more sensitivity and 100,000 times greater specificity than current genomic detection systems. Takara Bio Inc., Otsu, Japan, focuses on research and development of products and technologies in biotech research, gene and cell therapy, and nutraceuticals. Takara has a proven track record of high growth through research discoveries, technology development and the creation of strategic alliances with other industry leaders. Takara Bio's parent company is Takara Holdings, a $1.5 billion publicly traded company publicly traded company A company whose shares of common stock are held by the public and are available for purchase by investors. The shares of publicly traded firms are bought and sold on the organized exchanges or in the over-the-counter market. since 1949. For more information, visit http://www.takara.co.jp/english. Nanosphere, Inc. is a nanotechnology-based life sciences company in Northbrook, Illinois that is focused on developing assays for genomic and proteomic research, clinical laboratories and point-of-care markets. For more information about Nanosphere, visit http://www.nanosphere-inc.com or call 773-665-7650. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion